Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
VIVir Biotechnology, Inc. logo

Vir Biotechnology, Inc. (VIR)

NASDAQ Global Select · Currency in USD
$10.57 ▲ +0.14 (+1.34%)
At close: Oct 23, 4:00 PM ET. Market closed.
$10.57 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$10.43
Open
$10.36
Day's Range
$10.03 – $10.59
52 Week Range
$4.82 – $12.00
Volume
1,693,540
Avg. Volume
2,005,848
Market Cap
$1.79B
Beta (5Y Monthly)
1.59
PE Ratio (TTM)
--
EPS (TTM)
-$1.50
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$23.50

Profile: Vir Biotechnology, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
367
CEO
Marianne De Backer
Website
vir.bio

Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate -$0.74 · Revenue est. $858.88K
DateEst.Actual
Aug 5, 2026$0.33$0.47Beat
May 6, 2026-$0.01-$0.85Miss
Feb 23, 2026-$0.42-$0.31Beat
Nov 5, 2025-$0.70-$1.17Miss
Aug 6, 2025-$0.72-$0.80Miss
May 7, 2025-$0.83-$0.88Miss

Analyst view

Consensus price target
$23.50 ▲ +122.3%
Range $22.00 – $25.00
Rating: Buy
Buy 83% · Hold 17% · Sell -0%

Get free alerts on VIR and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.